Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEMVAC in Triple-Negative Breast Cancer
NCT07721259Phase 2Not yet recruiting
- Sponsor
- University of Washington
- Start
- Nov 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of STEMVAC in triple-negative breast cancer (TNBC), sponsored by University of Washington. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
STEMVAC
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07721259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07721259.